非小細胞肺癌（NSCLC）患者を対象とした手術または放射線治療後のセルペルカチニブに関する研究

基本情報

NCT ID

NCT04819100

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

152

治験依頼者名

Eli Lilly and Company

概要

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)